Armando Mansilha

Armando Mansilha


Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in Annals of Vascular Surgery
Verified
Journal Article
Closed access
RCRicardo Castro-Ferreira
Ricardo Castro-Ferreira
RCRita Cardoso
Rita Cardoso
AMAdelino Leite Moreira
Adelino Leite Moreira
AMArmando Mansilha
Armando Mansilha

1 December 2010 in European Journal of Vascular and Endovascular Surgery
Verified
Journal Article
Closed access
RLR. Launois
R. Launois
AMArmando Mansilha
Armando Mansilha
GJG. Jantet
G. Jantet

25 September 2011 in Quality of Life Research
Verified
Journal Article
Closed access
PDF file
RLR. Launois
R. Launois
JMJ. G. Le Moine
J. G. Le Moine
FLF. S. Lozano
F. S. Lozano
AMArmando Mansilha
Armando Mansilha

1 January 2022 in European Journal of Vascular and Endovascular Surgery
Verified
Journal Article
Open access
ACAndreia Coelho
Andreia Coelho
JPJoão Peixoto
João Peixoto
AMArmando Mansilha
Armando Mansilha
ANA. Ross Naylor
A. Ross Naylor
Gert Jan de BorstGert Jan de Borst
Gert Jan de Borst
This review aimed to analyse the timing of carotid endarterectomy (CEA) and carotid artery stenting (CAS) after the index event as well as 30 day outcomes at varying time periods within 14 days of symptom onset. A systematic review was performed according to the Preferred Reporting Items for Systematic reviews and Meta-analysis statement, comprising an online search of the Medline and Cochrane databases. Methodical quality assessment of the included studies was performed. Endpoints included procedural stroke and/or death stratified by delay from the index event and surgical technique (CEA/CAS). Seventy-one studies with 232 952 symptomatic patients were included. Overall, 34 retrospective analyses of prospective databases, nine prospective, three RCT, three case control, and 22 retrospective studies were included. Compared with CEA, CAS was associated with higher 30 day stroke (OR 0.70; 95% CI 0.58 - 0.85) and mortality rates (OR 0.41; 95% CI 0.31 - 0.53) when performed ≤ 2 days of symptom onset. Patients undergoing CEA/CAS were analysed in different time frames (≤ 2 vs. 3 - 14 and ≤ 7 vs. 8 - 14 days). Expedited CEA (vs. 3 - 14 days) presented a sampled 30 day stroke rate of 1.4%; 95% CI 0.9 - 1.8 vs. 1.8%; 95% CI 1.8 - 2.0, with no statistically significant difference. Expedited CAS (vs. 3 - 14 days) was associated with no difference in stroke rate but statistically significantly higher mortality rate (OR 2.76; 95% CI 1.39 - 5.50). At present, CEA is safer than transfemoral CAS within 2/7 days of symptom onset. Also, considering absolute rates, expedited CEA complies with the accepted thresholds in international guidelines. The ideal timing for performing CAS (when indicated against CEA) is not yet defined. Additional granular data and standard reporting of timing of intervention will facilitate future monitoring.

1 September 2019 in International Angiology
Verified
Journal Article
Closed access
AMArmando Mansilha
Armando Mansilha
JSJoel Sousa
Joel Sousa
Lower limb varicose veins can be treated effectively with endovenous ablation procedures or with minimally invasive open techniques. However, these procedures may cause pain and discomfort, and surgical stripping can be associated with long recovery times. We investigated whether venoactive drugs (VAD) used to treat chronic venous disease (CVD), provide benefits to patients recovering from a surgical or endovenous varicose vein procedure. We conducted a systematic review of the literature to identify clinical trials investigating VAD therapy before, during, or after a surgical, endovenous, or sclerotherapy procedure for varicose veins. Records retrieved from the PubMed and Embase databases were screened for relevant studies. Full-length articles in English were obtained for analysis. We identified five clinical trials investigating the effects of VAD on recovery after surgery, endovenous ablation, or sclerotherapy. Studies were conducted in Russia, Italy, and Czech Republic and varied considerably in design, but all were unblinded open-label studies. All studies reported the use of micronized purified flavonoid fraction (MPFF); in one study, sulodexide was also used. Three studies reported significantly less post-procedural pain with MPFF treatment, with one reporting no significant effect. Two studies reported significant reductions in post-procedural bleeding with MPFF treatment. Three out of four studies reported greater symptomatic improvement with MPFF treatment. Appropriate treatment with MPFF may help reduce post-procedural pain, hemorrhage, and CVD-specific symptoms. While adjunct VAD treatment seems promising, high-quality placebo-controlled studies are needed to unequivocally demonstrate its benefits.

1 November 2005 in European Journal of Vascular and Endovascular Surgery
Verified
Journal Article
Closed access
AMArmando Mansilha
Armando Mansilha
FAFERNANDO MANUEL FERREIRA ARAUJO
FERNANDO MANUEL FERREIRA ARAUJO
MSM. Severo
M. Severo
SSS.M. Sampaio
S.M. Sampaio
TTT. Toledo
T. Toledo
RAR. Albuquerque
R. Albuquerque